Fig. 1
From: Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Real time qPCR analysis of immune checkpoint genes as PD-L1, CTLA4, TIM3, and Ido-1 expressed by spheroids untreated (Control) or treated with selumetinib (Mek-i), atezolizumab (anti-PD-L1) or their combinations. Results were normalized to 18S mRNA and analyzed by ΔCt method. One-way ANOVA test followed by Tukey’s test were used for statistical analysis. **p < 0.01